New therapies for a serious impairment can be problematic from a risk classification perspective because insured lives data would not be available to provide guidance when these individuals later apply for insurance coverage. This paper analyzes one of the world's largest series, which asked the question What is the long-term mortality and morbidity risk among patients who have already survived for five or more years after bone marrow transplantation? From NAAJ, July 1999, Volume 3, Number 3.

The Critical Illness Insurance Forum is a unique, interactive event for individuals involved in the development, distribution, or administration of Critical Illness Insurance products.

In an effort to build a bridge between epidemiological and actuarial modeling, this paper analyzes possible financial arrangements made against expenses resulted from medical treatments given to insured patients. Based on classical compartment models, the first part of this paper designs insurance policies for susceptible participants facing the risk of infection and formulates the financial obligations of both parties using actuarial methodology. For practical purposes, the second part employs a variety of numerical methods for calculating premiums and reserves. The last part illustrates the methods by designing insurance products for the Great Plague in Eyam and the SARS Epidemic in Hong Kong.

A review of teleunderwriting outside the United States – how different market environments have shaped the models adopted. From the Fifth Annual Society of Actuaries Teleunderwriting Seminar in February 2009.

A presentation from the SOA 08 Annual Meeting. This session sought to explain: • The concept of critical illness insurance • Consumer needs and attitudes • Target markets • Effective marketing materials • The basics of sales training and • Canadian and U.S. sales results for individual and group products.

This paper is the first of two parts. It constructs a model for the development of coronary heart disease CHD or stroke that either incorporates, or includes pathways through, the najor risk factors of interest when underwriting for critical illness insurance. Its main purpose is to develop a model that could be used to assess the impact on insurance underwriting of genetic information relevant to CHD and/or stroke. The model is parameterized using data from the Framingham Heart Study in the United States.

This paper consists of 2 parts. This part extends the model of Part I to include other critical illnesses, such as cancers and kidney failure, and describes some applications of the model. In particular, CI premium ratings for applicants with combinations of some or all of high body mass index, smoking, high blood pressure, high cholesterol, and diabetes are discussed. This paper also considers the possible effect on CI premium ratings of genetic conditions that increase the likelihood of high blood pressure, high cholesterol, diabetes, CHD event, or stroke.

Adult Polycystic Kidney Disease APKD is a single-gene autosomal dominant genetic disorder leading to end-stage renal disease. In this paper we model the impact of mutations in APKD1 or APKD2 on critical illness insurance, which was based on studies predating DNA-based tests. From NAAJ, January 2007, Volume 11, Number 1.

Adult polycystic kidney disease APKD is a single-gene autosomal dominant genetic disorder leading to end-stage renal disease ESRD, meaning kidney failure. It is associated with mutations in at least two genes, APKD1 and APKD2, but diagnosis is mostly by ultrasonography. We propose a model for critical illness CI insurance and estimate rates of onset of ESRD from APKD using two studies. Other events leading to claims under CI policies are included in the model, which we use to study a extra premiums under CI policies if the presence of an SPKD mutation is known, and B the possible costs arising from adverse selection if this information is unavailable to insurers. From NAAJ, April 2003, Volume 7, Number 2.

Presentation from the 2009 Health Spring Meeting which covers the critical illness product as applied in many countries around the world.